Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 01 2017 - 4:05PM
Business Wire
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical
company focused on delivering innovative therapies to patients with
kidney disease through the biology of hypoxia-inducible factor
(HIF), today announced that the Company granted three newly-hired
employees options to purchase an aggregate of 45,500 shares of
Akebia's common stock with a per share exercise price
of $15.56, the closing price on the grant date. These options
will vest as to 25% of the total number of shares subject to the
option on the first anniversary of the grant date. The remaining
75% of shares will vest ratably on the first day of each calendar
quarter over the next three years. The stock options were
inducements material to these new employees entering into
employment with the Company, and issued in reliance on NASDAQ
Listing Rule 5635(c)(4).
About Akebia TherapeuticsAkebia Therapeutics,
Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative
therapies to patients with kidney disease through hypoxia-inducible
factor biology. Akebia’s lead product candidate, vadadustat, is an
oral, investigational therapy in development for the treatment of
anemia related to chronic kidney disease in both non-dialysis and
dialysis patients. Akebia’s global Phase 3 program for vadadustat,
which includes the PRO2TECT studies for non-dialysis patients with
anemia secondary to chronic kidney disease and the INNO2VATE
studies for dialysis-dependent patients, is currently ongoing. In
addition, the Company has initiated the Phase 2 FO2RWARD study of
vadadustat in dialysis-dependent chronic kidney disease patients
who are hyporesponsive to erythropoiesis-stimulating agents (ESAs),
and expects to commence the Phase 3 TRILO2GY study to further
evaluate a three-times-weekly dosing regimen for vadadustat. For
more information, please visit our website
at www.akebia.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171201005075/en/
Akebia TherapeuticsJohn Garabo, 617-844-6130Director,
Corporate Communicationsjgarabo@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2023 to Apr 2024